These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 28726049

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 25. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
    Aydinlar EI, Dikmen PY, Kosak S, Kocaman AS.
    J Headache Pain; 2017 Dec 15; 18(1):23. PubMed ID: 28213829
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The Effect of OnabotulinumtoxinA on Headache Intensity and Number of Monthly Headache Days in Individuals with Chronic Migraine with Different Levels of Neck Disability.
    Onan D, Arıkan H, Martelletti P.
    Toxins (Basel); 2023 Dec 06; 15(12):. PubMed ID: 38133189
    [Abstract] [Full Text] [Related]

  • 29. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 06; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 30. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Jan 22; 20(1):10. PubMed ID: 30669961
    [Abstract] [Full Text] [Related]

  • 31. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 22; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 32. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL.
    J Headache Pain; 2016 Dec 22; 17(1):112. PubMed ID: 27957623
    [Abstract] [Full Text] [Related]

  • 33. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, Tu YH, Tzeng YS, Chen SP, Fuh JL, Lai KL, Ling YH, Chen WT, Wang SJ.
    Eur J Neurol; 2024 Sep 22; 31(9):e16372. PubMed ID: 38837528
    [Abstract] [Full Text] [Related]

  • 34. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
    Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D.
    J Neural Transm (Vienna); 2016 May 22; 123(5):533-40. PubMed ID: 27032774
    [Abstract] [Full Text] [Related]

  • 35. OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.
    Ranoux D, Martiné G, Espagne-Dubreuilh G, Amilhaud-Bordier M, Caire F, Magy L.
    J Headache Pain; 2017 Dec 22; 18(1):75. PubMed ID: 28733943
    [Abstract] [Full Text] [Related]

  • 36. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 37. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
    Artemenko AR, Abramov VG, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Yakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Apr 16; 123(5):89-99. PubMed ID: 37315247
    [Abstract] [Full Text] [Related]

  • 38. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 16; 30(7):793-803. PubMed ID: 20647170
    [Abstract] [Full Text] [Related]

  • 39. Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA.
    Martínez-Pías E, Guerrero ÁL, Sierra Á, Trigo J, García-Azorín D.
    Toxins (Basel); 2021 Jun 21; 13(6):. PubMed ID: 34205832
    [Abstract] [Full Text] [Related]

  • 40. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
    Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J.
    Cephalalgia; 2015 Sep 21; 35(10):864-8. PubMed ID: 25431141
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.